Skip to main content
. 2020 May 4;24(12):6750–6761. doi: 10.1111/jcmm.15326

FIGURE 4.

FIGURE 4

Clinical relevance of SOX3 in gastric cancer. A, Serum SOX3 level was higher in advanced cancer patients than in early cancer patients (P = .039). B, SOX was highly expressed in advanced gastric cancer tissues compared with that in early tumour. C, The overall survival (OS) of 304 gastric cancer patients was negatively associated with the SOX3 levels in tumour tissue (P = .0002). D, Stratified analyses indicated that the SOX3 levels in tumour tissues were correlated with the OSs in both patients of pTNM stage Ⅰ/Ⅱ (P = .016) and stage Ⅲ/Ⅳ (P = .015) conversely